Company: ARWR
Filing Date: 2025-01-29
Form Type: DEF 14A
Source: 0001628280-25-002848
Chunk: 47

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: DEF 14A
Chunk 47
---
284,800 |     |    |     |                                   252,000 |     |    |     |                    14,715 |     |           |  3,095,982 |
|                                               |     | 2022 |     | 479,170 |     |      — |     |               — |     |    |     |                                   225,574 |     |    |     |                         — |     |           |    704,744 |
| Tracie Oliver (8)                             |     | 2024 |     | 484,065 |     |      — |     |       2,589,750 |     |    |     |                                         — |     |    |     |                     2,965 |     |           |  3,076,780 |
| Former Chief Commercial Officer               |     | 2023 |     | 647,261 |     |      — |     |          19,040 |     |    |     |                                   188,000 |     |    |     |                    19,521 |     |           |    873,822 |
|                                               |     | 2022 |     | 111,154 |     | 16,344 |     |       2,517,200 |     |    |     |                                    94,874 |     |    |     |                     4,899 |     |           |  2,744,471 |

(1) This column represents the total grant date fair value, computed in accordance with ASC 718, of RSUs granted during fiscal years 2024, 2023 and 2022. The assumptions used to calculate the value of the stock underlying the RSU awards are set forth in Note 9 of the Notes to the Consolidated Financial Statements included with the Company’s Annual Report on Form 10-K. (2) These bonus amounts represent the amounts earned for performance under the Company’s Annual Bonus Incentive Plan during calendar years 2024, 2023 and 2022 and paid in fiscal years 2025, 2024 and 2023, respectively. The Annual Bonuses are described in more detail in the “Bonus Incentive” section. (3) Amounts consist of 401(k) matching contribution, as well as life insurance premiums for the benefit of each executive officer.

| 44 |

2025 PROXY STATEMENT Executive Compensation (4) The amount reported for Christopher Anzalone